Background: Statins reduce cardiovascular disease risk and affect endothelial function by
INTRODUCTION
Statins are widely prescribed lipid-lowering drugs that significantly reduce cardiovascular morbidity and mortality in many different patient populations, as demonstrated in multiple large primary and secondary prevention trials [1] [2] [3] [4] [5] [6] [7] [8] [9] . By inhibiting 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of cholesterol biosynthesis, statins reduce both total and low-density lipoproteinassociated cholesterol (LDL-associated cholesterol). Their beneficial effects in cardiovascular disease (CVD) patients have been largely attributed to their efficacy to lower LDL-associated cholesterol [4] . Statins, also have additional pleiotropic (cholesterol-independent) effects, many of which are mediated by the vascular endothelium [10] [11] [12] [13] [14] [15] [16] [17] . However, data from several, mainly in vitro studies, may be difficult to interpret since statins were used at pharmacological and possibly cytotoxic concentrations or in combination with a variety of agonists like TNF-, endotoxin or thrombin [13, 16] . The existence of pleiotropic effects of statins in vivo, separate from their cholesterol-lowering potential, was recently substantiated by Landmesser et al, who
showed improvement of endothelial dysfunction in patients with chronic heart failure after simvastatin therapy but not after treatment with the cholesterol absorption inhibitor ezetimibe, given at a dose that lowered LDL-associated cholesterol to a similar extent [18] .
Pleiotropic effects of statins seem to be mainly caused by inhibition of protein prenylation. Prenylation is a post-translational mechanism of protein modification, in which intermediates of the mevalonate pathway, like geranylgeranylpyrophosphate (GGPP), are attached to proteins. Geranylgeranylated proteins, including the small G proteins Rho, Rac and Rab, bind to cell membranes and are required for transmembrane signaling [19] . As a consequence, G proteins are involved in the regulation of cell growth, differentiation, gene expression, cytoskeletal assembly and cell motility, formation of microparticles (MP) or "apoptotic bodies", protein and lipid trafficking, nuclear transport and host defense [19] . Thus, by preventing formation of mevalonate, statins block cholesterol biosynthesis and transmembrane signaling.
Previously, we showed that cultures of viable and unstimulated human umbilical vein endothelial cells (HUVEC) contain small numbers of detached cells ('floaters') undergoing apoptosis as well as endothelial cell-derived MP (EMP) [20] . Since in the aforementioned in vitro studies no or hardly any attention was paid to detachment and/or release of EMP, we hypothesized that to gain insight into the full response of endothelial cells to statins, not only the adherent cell fraction but also the corresponding fraction of detached cells and EMP have to be analyzed. Therefore, in order to study the true impact of statins on the endothelium, we determined the effect of simvastatin on human endothelial cells by concurrently analyzing adherent cells, detached cells and EMP.
MATERIALS AND METHODS

Reagents and assays
Medium M199, penicillin, streptomycin, Isocove's modified dulbecco's medium and L-glutamine were obtained from GibcoBRL, Life Technologies (Paisley, Scotland).
Human serum and fetal calf serum (both heat inactivated during 30 minutes at 56 ºC; HuSi and FCSi, respectively) were from BioWhittaker (Walkersville, MD). Human serum albumin (HSA) was obtained from Sanquin (Amsterdam, The Netherlands). Human recombinant basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) were obtained from Invitrogen life technologies (Carlsbad, CA). Collagenase (type 1A), geranylgeranylpyrophosphate (GGPP), mevalonolactone (mevalonate) and propidium iodide (PI) were from Sigma (St. Louis, MO). APC-labeled annexin V was from Caltag Laboratories (Burlingame, CA). Heparin (400 U/mL) was from Leo Pharma BV (Breda, The Netherlands), trypsin from Difco Laboratories (Detroit, MI), and simvastatin from Calbiochem (Darmstadt, Germany). Tissue culture flasks were from Greiner Labortechnik (Frickenhausen, Germany) and gelatin from Difco Laboratories (Sparks, MD). Stock solutions of simvastatin, mevalonate and GGPP were prepared in ethanol, ethanol and methanol, respectively. Antibodies against (pro-)caspase 9, (pro-)caspase 8 and caspase 3 for Western blotting were obtained from Cell Signaling (Beverly, MA). Anti-procaspase 3 was from Transduction Laboratories (San Diego, CA). Secondary antibodies used for Western blot, i.e. goat-anti-mouse HRP conjugate and anti-rabbit HRP conjugate, were from Biorad (Hercules, CA) and Promega (Madison, USA), respectively. FITC-labeled annexin V was from Immuno Quality Products (Groningen, The Netherlands).
Isolation, culture and treatment of HUVEC HUVEC were collected from human umbilical cord veins as described previously [20] . Briefly, umbilical cords were digested with collagenase for 20 minutes at 37 °C. 1 ng/mL used in our present study [21, 22] . determine the apoptosis status of the endothelial cells was performed as described previously [20] .
Flow cytometric analysis of endothelial cells
Isolation of EMP
Aliquots ( All antibodies were diluted with blocking buffer. The bands were detected using LumLight Plus Western Blotting Substrate (Roche; Mannheim, Germany) and exposed to Fuji Medical X-ray film.
Statistical analysis
Data were analyzed with GraphPad Prism for Windows (release 3.02; San Diego, CA). Differences were analyzed by t-test for independent samples and were considered to be significant at P<0.05. All data are presented as mean ± SD. Data were obtained from at least 3 independent experiments, i.e. using endothelial cell cultures from 3 or more different umbilical veins. Data were compared to ethanol-(EtOH) and methanol (MeOH)-treated endothelial cell cultures.
RESULTS
Simvastatin induces endothelial cell detachment
Upon incubation with simvastatin, the detached cell fraction ( Figure 1A 
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HUVEC were incubated without (A, C, E, G) or with (B, D, F, H) simvastatin (1.0 μmol/L) for 24 hours. Adherent (A-D) and detached cells (E-H) were stained with annexin V (A, B, E, F) or PI (C, D, G, H).
Effect of simvastatin on EMP formation
Upon incubation with either 1.0 or 5.0 μmol/L simvastatin, the numbers of caspase 3-containing EMP increased ( Figure 4A ; C and D, respectively) when compared to control ( Figure 4A ; A) or vehicle ( Figure 4A; B) . The numbers of annexin V-binding and caspase 3-containing EMP increased 2.5-fold in the presence of simvastatin ( Figure 4B ). This increase tended to be statistically significant at 1.0 μmol/L simvastatin and reached statistical significance at 5.0 μmol/L simvastatin (P=0.098 and P=0.041, respectively).
Co-incubation with either mevalonate or GGPP completely abolished the statin-induced EMP release. The insert of Figure 4B confirms the presence of caspase 3 in EMP lysates.
Both mevalonate and GGPP completely prevented the observed (simvastatin-induced) increase in caspase 3 formation (data not shown). Thus, prenylation counteracts the simvastatin-induced release of (caspase 3-containing) EMP.
Role of caspases in statin-induced cell detachment
Active caspase 3 (17 kDa) is a cleavage product of the inactive 32 kDa precursor (procaspase 3). Induction of programmed cell-death, either via death receptors ('extrinsic') or via leakage of mitochondrial cytochrome C ('intrinsic'), ultimately leads to cleavage of procaspase 3 by either caspase 8 ('extrinsic') or caspase 9 ('intrinsic'). Figure   5 shows that only procaspases 8 (57 kDa) and 9 (47 kDa) were detectable in adherent cell lysates, and their relative quantities seemed unaffected by simvastatin. In contrast, detached cells and to a lesser extent EMP contained detectable quantities of caspase 8 (43 kDa) after incubation with simvastatin, but not caspase 9 (35-37 kDa). Caspase 8 was not detectable when cells were co-incubated with mevalonate or GGPP (data not shown).
Since caspase 8 but not caspase 9 is detectable in detached cell lysates from simvastatintreated cultures, we hypothesize that cleavage of procaspase 8 may explain the observed increase in caspase 3 under these conditions. 
DISCUSSION
Incubation of human endothelial cells with simvastatin at clinically relevant doses triggered endothelial cell detachment as well as EMP release. Lysates from both detached cells and EMP contained substantial quantities of caspases 3 and 8, whereas caspase 9 remained below the detection limit, suggesting that caspase 8 formation underlies the formation of caspase 3 under these conditions. Previously, statins were shown to induce apoptosis of keratinocytes via ligand-independent activation of caspase 8 via a death receptor [23] . Whether or not formation of caspase 8 precedes detachment or is a consequence of detachment ('anoikis'), however, remains to be determined.
Caspase 3 cleaves focal-adhesion kinase, thus eliminating essential cellular survival signals and thereby facilitating detachment. In addition, caspase 3 cleaves kinases like Rho-associated coiled kinase (ROCK)-I and p21-kinase, resulting in the formation of constitutively active kinases which directly contribute to formation of "apoptotic bodies" [24, 25] . Therefore, we hypothesize that -similar to keratinocytes-simvastatin may trigger caspase 8-mediated endothelial detachment and EMP release.
Our present data indicate that simvastatin-induced detachment and EMP release can be circumvented by restoring prenylation. Also, other investigators showed that statins induce apoptosis of endothelial cells in vitro, and in most studies these effects were counteracted by restoring prenylation. The extent by which statins induce apoptosis, however, seems to be dependent on the type of endothelial cell studied. With particular regard to HUVEC, however, statins induce a wide variety of effects, including enhanced expression of tissue factor and adhesion receptors, an increased release of EMP and augmented production and bioavailability of endothelium-derived NO [10, 12, 13, 16, [26] [27] [28] [29] [30] . In some of these studies, data are difficult to interpret since pharmacological and potentially cytotoxic concentrations of statins were used or statins were used only in combination with other endothelial agonists like TNF-or endotoxin. In most of these studies, however, solely adherent endothelial cells were studied. Our present data suggest that to appreciate the full scope of the statin effects on endothelial cells, all individual components of the incubation well, i.e. adherent cells, detached cells and MP, should be taken into account. In this regard, it should be mentioned that in some studies the apoptotic effects of statins on (adherent) endothelial cells could only be observed in the presence of additional inducers like TNF-, whereas in the present study the pro-apoptotic effect of statin-treatment alone became apparent when not only adherent cells but also detached cells and EMP were analyzed.
Whereas some potentially harmful adverse affects of statins have been reported on endothelial cells in vitro, these drugs have many beneficial effects on the endothelium in vivo. Statins increase the number and survival of circulating endothelial progenitor cells, facilitate re-endothelialization, inhibit endothelial senescence and increase cell proliferation by affecting cell cycle genes [31] . Thus, in spite of these seemingly contradictory reports, the existence of a discrepancy between in vitro versus in vivo effects of statins may be questioned. In our present study, we showed that adherent endothelial cells seemed unaffected by treatment with simvastatin despite increased numbers of both 'floaters' and EMP. Possibly, by facilitating detachment and EMP release, statins may improve the overall condition of the vascular endothelium.
Previously, we reported a strong correlation between the numbers of detached endothelial cells and EMP [20] . Also, our present data indicate a close association between cell detachment and EMP release. From such data, however, we may not conclude that EMP are released from detached cells since other investigators showed that EMP are released from still adherent cells during the process of detachment [24, 32] .
In summary, based on the present data we hypothesize that statins may facilitate cell detachment and EMP release in order to preserve the overall condition and antiatherogenic properties of the vascular endothelium. We suggest that, in order to gain full insight into the effects of compounds on endothelial cell biology, evaluation of adherent cells, detached cells as well as EMP should be adopted as a general methodological principle.
